Bill S-201, National Framework on Sickle Cell Disease Act, respecting provisions outlined in Section 2, subsections (a), (b), (e), and (i). Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board Innovation, Science and Economic Development Canada Innovation and Skills Strategy and other government policies and programs related to incentivizing research and development activities in Canada. Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries. Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases. Common Drug Review, as it relates to health technology assessments and drug product reimbursement recommendations.